Remidio, a provider of AI-powered ophthalmic solutions, has announced a strategic investment in Occuity, a UK-based developer of non-contact, handheld optical screening and monitoring devices. This move aims to expand non-invasive systemic disease screening, building on Remidio’s presence in AI-driven ophthalmic diagnostics.
Remidio and Occuity will integrate their technologies to develop a comprehensive myopia screening solution. India is expected to see a significant rise in myopia cases, with nearly 48 per cent of urban children affected by 2050. Of these, 20 per cent may experience rapid progression, and around 4 per cent could face complications leading to permanent vision loss. As part of this initiative, the collaboration will introduce India’s first handheld, non-invasive axial length measurement device for myopia detection and monitoring. The device will offer an alternative to complex and expensive eye exams, making early diagnosis more accessible, particularly for children. India has fewer than 20,000 primary eye care practitioners, including ophthalmologists, leading to gaps in timely screening and management. With Remidio’s distribution network and AI-powered diagnostics, the partnership aims to enable early myopia detection for millions of children across the country.
The collaboration will also introduce a handheld, non-contact device for assessing corneal thickness, a key factor in managing glaucoma and determining suitability for LASIK procedures. This technology will complement Remidio’s Comprehensive Eye Clinic in a Bag, expanding access to eye disease screening in remote and underserved areas.
Leveraging Remidio’s expertise in AI-powered diagnostics and scalable manufacturing, the partnership will accelerate the development and deployment of Occuity’s non-contact screening solutions. This includes the Occuity Indigo, an optical glucose meter that measures blood glucose levels through an eye scan, eliminating the need for finger-prick tests currently used by over 100 million diabetes patients in India. With 136 million pre-diabetics, the demand for early, painless detection is increasing. Occuity’s technology will enable early diabetes screening in community healthcare programmes, complementing Remidio’s AI-driven solutions for chronic eye diseases such as Diabetic Retinopathy, Glaucoma, and Macular Degeneration.
Dr Anand Sivaraman, CEO of Remidio, stated, “We believe that non-invasive diagnostics are the future of healthcare, particularly for large-scale public health challenges like diabetes and myopia. Occuity’s technology aligns perfectly with our mission to democratise high-quality screening and management, making preventive healthcare more accessible than ever before.”
Dr Dan Daly, CEO and Co-Founder of Occuity, added, “Remidio’s deep expertise in the design, development, and manufacturing of AI-integrated ophthalmic devices and their strong presence in the global ophthalmology market, including India, make them an ideal partner to expand the reach of our breakthrough non-contact screening devices. Their investment is a testament to our shared vision of transforming early disease detection and driving better patient outcomes globally.”